Literature DB >> 29745428

HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells.

N E James1,2, E Cantillo1, M T Oliver1, R B Rowswell-Turner3, J R Ribeiro1, K-K Kim3, C O Chichester2, P A DiSilvestro1, R G Moore3, R K Singh1,3, N Yano1, T C Zhao4.   

Abstract

Ovarian cancers are known to evade immunosurveillance and to orchestrate a suppressive immune microenvironment. Here we examine the role of human epididymis protein 4 (HE4), an ovarian cancer biomarker, in immune evasion. Through modified subtractive hybridization analyses we have characterized the gene targets of HE4 in human peripheral blood mononuclear cells (PBMCs), and established a preliminary mechanism for HE4-mediated immune failure in ovarian tumours. Upon exposure of purified PMBCs to HE4, osteopontin (OPN) and dual-specificity phosphatase 6 (DUSP6) emerged as the most suppressed and up-regulated genes, respectively. SKOV3 and OVCAR8, human ovarian carcinoma cell lines, exhibited enhanced proliferation in conditioned media from HE4-exposed PBMCs, an effect that was attenuated by the addition of recombinant OPN or OPN-inducible cytokines [interleukin (IL)-12 and interferon (IFN)-Ɣ]. Additionally, upon co-culture with PBMCs, HE4-silenced SKOV3 cells were found to be more susceptible to cytotoxic cell death. The relationship between HE4 and OPN was reinforced further through the analysis of serous ovarian cancer patient samples. In these biopsy specimens, the number of OPN+ T cells correlated positively with progression free survival (PFS) and inversely with serum HE4 level. Taken together, these findings show that HE4 enhances ovarian cancer tumorigenesis by compromising OPN-mediated T cell activation.
© 2018 British Society for Immunology.

Entities:  

Keywords:  T cells; cancer; cytokines

Mesh:

Substances:

Year:  2018        PMID: 29745428      PMCID: PMC6149960          DOI: 10.1111/cei.13153

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  The whey acidic protein family: a new signature motif and three-dimensional structure by comparative modeling.

Authors:  S Ranganathan; K J Simpson; D C Shaw; K R Nicholas
Journal:  J Mol Graph Model       Date:  1999-04       Impact factor: 2.518

2.  Osteopontin has a protective role in prostate tumor development in mice.

Authors:  Keiko Danzaki; Masashi Kanayama; Oscar Alcazar; Mari L Shinohara
Journal:  Eur J Immunol       Date:  2016-10-04       Impact factor: 5.532

3.  A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors.

Authors:  C Kirchhoff; I Habben; R Ivell; N Krull
Journal:  Biol Reprod       Date:  1991-08       Impact factor: 4.285

4.  Comprehensive analysis of HE4 expression in normal and malignant human tissues.

Authors:  Mary T Galgano; Garret M Hampton; Henry F Frierson
Journal:  Mod Pathol       Date:  2006-06       Impact factor: 7.842

5.  Specifically modified osteopontin in rheumatoid arthritis fibroblast-like synoviocytes supports interaction with B cells and enhances production of interleukin-6.

Authors:  Yasuhiro Take; Ken Nakata; Jun Hashimoto; Hideki Tsuboi; Norihiro Nishimoto; Takahiro Ochi; Hideki Yoshikawa
Journal:  Arthritis Rheum       Date:  2009-12

6.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

7.  Gene expression patterns in ovarian carcinomas.

Authors:  Marci E Schaner; Douglas T Ross; Giuseppe Ciaravino; Therese Sorlie; Olga Troyanskaya; Maximilian Diehn; Yan C Wang; George E Duran; Thomas L Sikic; Sandra Caldeira; Hanne Skomedal; I-Ping Tu; Tina Hernandez-Boussard; Steven W Johnson; Peter J O'Dwyer; Michael J Fero; Gunnar B Kristensen; Anne-Lise Borresen-Dale; Trevor Hastie; Robert Tibshirani; Matt van de Rijn; Nelson N Teng; Teri A Longacre; David Botstein; Patrick O Brown; Branimir I Sikic
Journal:  Mol Biol Cell       Date:  2003-09-05       Impact factor: 4.138

8.  Matricellular proteins: a sticky affair with cancers.

Authors:  Han Chung Chong; Chek Kun Tan; Royston-Luke Huang; Nguan Soon Tan
Journal:  J Oncol       Date:  2012-02-09       Impact factor: 4.375

9.  HE4 (WFDC2) gene overexpression promotes ovarian tumor growth.

Authors:  Richard G Moore; Emily K Hill; Timothy Horan; Naohiro Yano; KyuKwang Kim; Shannon MacLaughlan; Geralyn Lambert-Messerlian; YiTang Don Tseng; James F Padbury; M Craig Miller; Thilo S Lange; Rakesh K Singh
Journal:  Sci Rep       Date:  2014-01-06       Impact factor: 4.379

10.  HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.

Authors:  J R Ribeiro; C Schorl; N Yano; N Romano; K K Kim; R K Singh; R G Moore
Journal:  J Ovarian Res       Date:  2016-05-17       Impact factor: 4.234

View more
  3 in total

1.  A bioinformatic analysis of WFDC2 (HE4) expression in high grade serous ovarian cancer reveals tumor-specific changes in metabolic and extracellular matrix gene expression.

Authors:  Nicole E James; Megan Gura; Morgan Woodman; Richard N Freiman; Jennifer R Ribeiro
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.738

2.  The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.

Authors:  Nicole E James; Jenna B Emerson; Ashley D Borgstadt; Lindsey Beffa; Matthew T Oliver; Virginia Hovanesian; Anze Urh; Rakesh K Singh; Rachael Rowswell-Turner; Paul A DiSilvestro; Joyce Ou; Richard G Moore; Jennifer R Ribeiro
Journal:  Sci Rep       Date:  2020-05-22       Impact factor: 4.379

3.  Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure.

Authors:  Mintu Nath; Simon P R Romaine; Andrea Koekemoer; Stephen Hamby; Thomas R Webb; Christopher P Nelson; Marcos Castellanos-Uribe; Manolo Papakonstantinou; Stefan D Anker; Chim C Lang; Marco Metra; Faiez Zannad; Gerasimos Filippatos; Dirk J van Veldhuisen; John G Cleland; Leong L Ng; Sean T May; Federica Marelli-Berg; Adriaan A Voors; James A Timmons; Nilesh J Samani
Journal:  Eur J Heart Fail       Date:  2022-06-03       Impact factor: 17.349

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.